Chapter 26: Bones, Joints, and Soft Tissue Tumors

Bones, Joints, and Soft Tissue Tumors exploration of musculoskeletal pathology delves into the complex biological mechanisms governing the human skeletal system, joints, and soft tissues. It begins by establishing the physiological foundation of bone health, detailing the intricate balance of bone remodeling maintained by the RANK/RANKL/OPG signaling pathway and the coordinated activities of osteoblasts, osteocytes, and osteoclasts. The discussion transitions into developmental anomalies, distinguishing between localized dysostoses and global dysplasias, such as achondroplasia and thanatophoric dysplasia driven by FGFR3 mutations, and the brittle bone manifestations of osteogenesis imperfecta linked to type I collagen defects. Significant attention is given to metabolic bone diseases, particularly the high-turnover bone loss of postmenopausal osteoporosis and the disordered, mosaic-patterned architecture characteristic of Paget disease. The narrative covers the mechanical and infectious challenges to bone integrity, outlining the sequential stages of fracture healing and the destructive nature of pyogenic and mycobacterial osteomyelitis, including the spinal involvement known as Pott disease. A major portion of the chapter is dedicated to orthopedic oncology, classifying bone-forming, cartilage-forming, and mesenchymal tumors. Key malignancies like osteosarcoma, Ewing sarcoma, and chondrosarcoma are analyzed alongside benign but aggressive lesions such as giant cell tumors and aneurysmal bone cysts. The pathology of joints is examined through a comparative lens, contrasting the degenerative wear-and-tear of osteoarthritis with the autoimmune, pannus-forming inflammatory response of rheumatoid arthritis, while also addressing crystal-induced arthropathies like gout and pseudogout. Finally, the chapter categorizes soft tissue neoplasms, ranging from common lipomas to highly aggressive rhabdomyosarcomas and undifferentiated pleomorphic sarcomas, emphasizing the role of specific chromosomal translocations and molecular drivers in diagnosing these diverse mesenchymal malignancies.